MANE
Veradermics, Incorporated

Veradermics, IncorporatedMANE

Healthcare · Biotechnology
138.78USD
+7.92%
Nov 09, 2026
MANE overview ready
Developer of novel dermatologic therapeutics for hair loss and skin conditions
Veradermics, Incorporated is a clinical-stage biopharmaceutical company developing novel therapeutics for dermatologic and aesthetic conditions, focusing on treatments for hair loss and skin disorders through oral drugs and microarray patch technologies.
Theme not measured
No economic group is assigned yet.
An early price trend
Longer-term context reads new trend, with a near-term setup of daily advance.
Demanding valuation
This company carries a Expensive valuation stance that the scored components do not clearly support.
Fundamentals not measured
Market Nov 6Price action Nov 9

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction8.3BusinessPerformance—BusinessQuality—Valuation0.3ThemeMomentum—A revenue trend needs at least three unbroken comparable quarters, so none is read here.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

An early price trend
Longer-term context reads new trend, with a near-term setup of daily advance.
EntryConstructive

Structure is constructive on both timeframes without excessive extension — a reasonable entry location.

Key Financials

Market Cap
$5.8B
Provider figure at the stated date
Gross Margin
+0.0%
Trailing twelve months
Operating Margin
+0.0%
Trailing twelve months
Market metrics as of Nov 9, 2026

Business Performance

Insufficient evidence

A revenue trend needs at least three unbroken comparable quarters, so none is read here.

Latest reported: Q2 FY2026, ended Jun 30
Revenue growthNot enough data
—
— in Q2 FY2026 · no comparable year-ago quarter
Not enough comparable quarters for a YoY sequence.
Earnings growthLoss widening
-$23.5M
Net income -$23.5M. Per-share figures are not comparable across a large share-count change.
Not enough comparable diluted EPS quarters for a YoY sequence.
Operating marginNot enough data
—
No year-ago comparison

Business Quality

Not assessed

Not assessed yet — too few fiscal years of filings are on record.

Fundamentals & Valuation

Only one valuation perspective could be built for this company, and it reads expensive.
This company carries a Expensive valuation stance that the scored components do not clearly support. Treat it as unresolved.

What changed

Company Research

Research coverage for this company is in progress.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Veradermics, Incorporated is a clinical-stage biopharmaceutical company developing novel therapeutics for dermatologic and aesthetic conditions, focusing on treatments for hair loss and skin disorders through oral drugs and microarray patch technologies.

How it earns

The company is expected to generate revenue through product sales and licensing once its therapeutics receive regulatory approval and reach the market.

Products & services
VDPHL01 oral treatment for pattern hair loss
VDMN dissolvable microarray patch for common warts
VDAA treatment for alopecia areata
VDMC treatment for molluscum contagiosum
Customers & end markets
Patients with dermatologic conditions
Healthcare providers specializing in dermatology
Market position

Niche player focused on novel dermatologic therapies in early clinical development stages.

Demand drivers
Low cyclicality

Demand for dermatologic and aesthetic treatments tends to be stable and less sensitive to economic cycles.